373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2

• Yan Wang,
• John Powderly,
• Marc Ernstoff,
• Anthony Shields,
• Ulka Vaishampayan,
• John Wrangle,
• Sarina Piha-Paul,
• Anthony Olszanski,
• Lei Sun,
• Bradley Carthon,
• Kelly Curtis,
• Ilda Bidollari,
• Yangchun Du,
• Emily Putiri,
• Heather Losey,
• Bruce Dezube

Affiliations

Yan Wang

9Alkermes, Inc., Waltham, MA, USA

John Powderly

1Carolina BioOncology Institute, Huntersville, NC, USA

Marc Ernstoff

3Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Anthony Shields

6Wayne State University, Detroit, MI, USA

Ulka Vaishampayan

11University of Michigan, Detroit, MI, USA

John Wrangle

5Medical University of South Carolina, Charleston, SC, USA

Sarina Piha-Paul

1MD Anderson Cancer Center, Houston, TX, USA

Anthony Olszanski

4Fox Chase Cancer Center, Philadelphia, PA, USA

Lei Sun

9Alkermes, Inc., Waltham, MA, USA

Bradley Carthon

2Emory University School of Medicine, Atlanta, GA, USA

Kelly Curtis

8Syneos Health, Raleigh, NC, USA

Ilda Bidollari

9Alkermes, Inc., Waltham, MA, USA

Yangchun Du

9Alkermes, Inc., Waltham, MA, USA

Emily Putiri

9Alkermes, Inc., Waltham, MA, USA

Heather Losey

9Alkermes, Inc., Waltham, MA, USA

Bruce Dezube

9Alkermes, Inc., Waltham, MA, USA